SOURCE-LINKED STUDY SUMMARY
MitoQ supplementation augments acute exercise-induced increases in muscle PGC1α mRNA and improves training-induced increases in peak power independent of mitochondrial content and function in untrained middle-aged men.
Full paper summarizedQuality not appraised
- What was studied
- This randomized, double-blind trial tested whether the mitochondria-targeted antioxidant MitoQ changed acute exercise signaling or adaptations to short-term high-intensity interval training.
- Who / model studied
- Twenty-three untrained men, mean age 44 years, completed the parallel-group study.
- Studied dose & schedule
- Participants received oral MitoQ 20 mg/day or placebo for 10 days before one interval session, then continued through three weeks of HIIT performed three times weekly.
- What the study found
- MitoQ amplified PGC-1α mRNA and peak-power gains, but not VO2peak, 20-km performance, mitochondrial content/function, or measured oxidative-stress markers. No supplementation side effects were reported.
- Limitations & context
- The sample was small, male and untrained; training lasted only three weeks. A transcriptional signal did not translate into greater mitochondrial biogenesis, and the trial was not powered for uncommon harms.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.redox.2022.102341